Login to Your Account

Ambrx Enters China, Inks ZMC Deal for Breast Cancer Drug

By Shannon Ellis
Contributing Writer

Friday, June 21, 2013
SHANGHAI, China – In its first China deal, San Diego-based biopharma developer Ambrx Inc. will work with Zhejiang Medicine Co. (ZMC) to develop a new breast cancer drug.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription